# A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma

Source: https://onco.cc/trials/nct06787664/  
OnCo record `nct06787664` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Izalontamab brengitecan in chordoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma is a phase 2 interventional study registered as NCT06787664 by Sichuan Baili Pharmaceutical Co., Ltd., with 27 participants enrolled, started 2025-01-16 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1. Conditions listed: Chordoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06787664
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Locally Advanced or Metastatic Chordoma
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT06787664: https://clinicaltrials.gov/study/NCT06787664

## Connected records

- cancers: [Chordoma](https://onco.cc/cancers/chordoma/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06787664.json